Further deepening its commitment to China, Quintiles today announced the launch of Kun Tuo, a local contract research organization (CRO) built to service the unique needs of the Chinese biopharmaceutical industry and multinational biopharma companies operating in China.
Building on Quintiles' unmatched success at the global level and experience in conducting clinical trials in China since 1997, Kun Tuo will focus on developing customized solutions to help local and global biopharma companies achieve successful registration of new medicines in China.
Kun Tuo will provide a full range of services, including comprehensive clinical trial management, regulatory submission preparation, biostatistics and data management. Kun Tuo will tap Quintiles' global resources and expertise to develop customized offerings in key therapeutic areas, along with vaccines, late phase studies, medical devices and diagnostics.
"Kun Tuo will leverage Quintiles' quality and training systems to offer customized, high-quality solutions best suited for local Chinese biopharma, as well as global biopharma local affiliates," said Ling Zhen, General Manager, Quintiles China. "We have an aggressive growth plan for China and anticipate doubling Quintiles total staff during 2012 as we look to provide our customers with the solutions they need to succeed in one of the world's most dynamic marketplaces."
New AI tool maps millions of CD8+ T cells to advance disease research